Stock Research for IMMY


Featured Broker: Ally Invest

Get the due diligence for another stock.


IMMY Stock Chart & Research Data

The IMMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


IMMY Due diligence Resources & Stock Charts

The IMMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IMMY Detailed Price Forecast - CNN Money CNN View IMMY Detailed Summary - Google Finance
Yahoo View IMMY Detailed Summary - Yahoo! Finance Zacks View IMMY Stock Research & Analysis -

Stock Analysis

TradeIdeas View IMMY Trends & Analysis - Trade-Ideas Barrons View IMMY Major Holders - Barrons
NASDAQ View IMMY Call Transcripts - NASDAQ Seeking View IMMY Breaking News & Analysis - Seeking Alpha
Spotlight View IMMY Annual Report - OTC Report View IMMY OTC Short Report -
TradeKing View IMMY Fundamentals - TradeKing Charts View IMMY SEC Filings - Bar Chart
WSJ View Historical Prices for IMMY - The WSJ Morningstar View Performance/Total Return for IMMY - Morningstar
MarketWatch View the Analyst Estimates for IMMY - MarketWatch CNBC View the Earnings History for IMMY - CNBC
StockMarketWatch View the IMMY Earnings - StockMarketWatch MacroAxis View IMMY Buy or Sell Recommendations - MacroAxis
Bullish View the IMMY Bullish Patterns - American Bulls Short Pains View IMMY Short Pain Metrics -

Social Media Mentions

StockTwits View IMMY Stock Mentions - StockTwits PennyStocks View IMMY Stock Mentions - PennyStockTweets
Twitter View IMMY Stock Mentions - Twitter Invest Hub View IMMY Investment Forum News - Investor Hub
Yahoo View IMMY Stock Mentions - Yahoo! Message Board Seeking Alpha View IMMY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for IMMY - Insider Cow View Insider Transactions for IMMY - Insider Cow
CNBC View IMMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IMMY - OTC Markets
Yahoo View Insider Transactions for IMMY - Yahoo! Finance NASDAQ View Institutional Holdings for IMMY - NASDAQ

Stock Charts

FinViz View IMMY Stock Insight & Charts - StockCharts View IMMY Investment Charts -
BarChart View IMMY Stock Overview & Charts - BarChart Trading View View IMMY User Generated Charts - Trading View

Latest Financial News for IMMY

Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?
Posted on Friday April 20, 2018

Mark Baum took the helm as Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO and grew market cap to US$45.45M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
Posted on Tuesday April 10, 2018

New combination topical drops and other cGMP (current good manufacturing practices) formulations will be showcased SAN DIEGO , April 10, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ...

Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
Posted on Tuesday March 27, 2018

SAN DIEGO, March 27, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron) Melt® compounded formulation from the US Patent and Trademark office.  US Patent 9,918,993 B2 entitled "Pharmaceutical compositions for anesthesiological applications" was issued on March 20, 2018. Imprimis believes that beyond cataract surgery, there are likely more than 100 million annual procedures in the US ranging from dental, obstetric and gynecological, medical imaging procedures (such as MRIs and CAT scans), vasectomies, colonoscopies, dermatological, plastics procedures, orthopedic, otolaryngological, podiatry, emergency room, urology, and psychiatric that may benefit from an IV-free and opioid-free formulation.

Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Monday March 19, 2018

NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

Enter a stock symbol to view the stock details.